Diseases that involve inflammasome activation and IL-1β production can result in vascular changes, e.g., SIRS patients experience increased microvascular permeability, platelet sludging, maldistribution of blood flow, and activation of the coagulation system, among other symptoms [45], [46]. This evidence concerns the gene IL1B and systemic inflammatory response syndrome.